|
|
|
|
| LEADER |
01779nam a2200301 u 4500 |
| 001 |
EB001888669 |
| 003 |
EBX01000000000000001052030 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
200106 r ||| eng |
| 245 |
0 |
0 |
|a HPV testing for primary cervical cancer screening
|h Elektronische Ressource
|b recommendations report
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c March 2019, 2019
|
| 300 |
|
|
|a 1 PDF file (22 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Liquid Biopsy
|
| 653 |
|
|
|a Uterine Cervical Neoplasms / diagnosis
|
| 653 |
|
|
|a Papanicolaou Test
|
| 653 |
|
|
|a Outcome Assessment, Health Care
|
| 653 |
|
|
|a Human Papillomavirus DNA Tests
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH optimal use report
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK543306
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 140
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a CADTH undertook a Health Technology Assessment (HTA) to inform policy decisions through a review of the evidence relating to clinical effectiveness and safety, cost-effectiveness, patients' perspectives and experiences, ethical issues, and implementation issues regarding the use of HPV versus cytology-based primary cervical cancer screening programs. The HTA informed the following policy questions: Should HPV testing replace cervical cytology in Canadian jurisdictions as the primary screening tool for cervical cancer? If yes, what criteria, including appropriate screening interval and ages to start and stop screening, should guide HPV-based cervical cancer screening programs in Canada?
|